Neurology-Neuroimmunology & Neuroinflammation

Article	Citations
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes	374
Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID	120
Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome	109
Neurosarcoidosis	106
Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalitis Following COVID-19	90
International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis	88
Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France	85
Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis	84
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders	79
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19	74
COVID-19 Among Patients With Multiple Sclerosis	72
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis	68
Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders	68
Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression	61
Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease	60
Presentations and mechanisms of CNS disorders related to COVID-19	57
IgG4-Mediated Neurologic Autoimmunities	56
COVID-19 Severity in Multiple Sclerosis	56
New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD	54
Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF	53
Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis	53
Retinal Optical Coherence Tomography in Neuromyelitis Optica	53
Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection	49
Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder	47
Anti-CD20 therapies and pregnancy in neuroimmunologic disorders	46

Chitinases and chitinase-like proteins as biomarkers in neurologic disorders	46
Immune profiling of plasma-derived extracellular vesicles identifies Parkinson disease	45
Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder	45
Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab	45
Anti-IgLON5 Disease	44
Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis	44
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS	43
Toward Precision Phenotyping of Multiple Sclerosis	41
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis	41
Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders	40
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection	39
Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies	39
Seizure-related 6 homolog like 2 autoimmunity	39
Gene-Environment Interactions in Multiple Sclerosis	38
Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children	38
Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes	38
Targeting B Cells to Modify MS, NMOSD, and MOGAD	36
Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation	35
Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors	35
Cladribine vs other drugs in MS	35
Microglia Activation in Basal Ganglia Is a Late Event in Huntington Disease Pathophysiology	34
Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 Antibodies	34
Microglia as Central Protagonists in the Chronic Stress Response	34
Abnormal B-Cell and Tfh-Cell Profiles in Patients With Parkinson Disease	34
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis	34
Thymoma and Autoimmune Encephalitis	33
Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-specific Manner	33
Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis	33
Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis	33
CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis	32
Updated Results of the COVID-19 in MS Global Data Sharing Initiative	32
Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions	32
Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity	32
Progranulin Suppressed Autoimmune Uveitis and Autoimmune Neuroinflammation by Inhibiting Th1/Th17 Cells and Promoting Treg Cells and M2 Macrophages	31
Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy	31
Heterogeneity of Acetylcholine Receptor Autoantibody–Mediated Complement Activity in Patients With Myasthenia Gravis	31
Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome	31
Potential Role of CHI3L1+ Astrocytes in Progression in MS	30
Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis	30
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors	30
High serum neurofilament associates with diffuse white matter damage in MS	30
Systemic Inflammation Is Associated With Neurologic Involvement in Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2	30
Risk of Getting COVID-19 in People With Multiple Sclerosis	30
Incidence and Impact of COVID-19 in MS	30
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD	30
Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS	30
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis	29
Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy	29
Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4	29
Primary Angiitis of the CNS	29

Serum neurofilament light chain	29
Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated Diseases	28
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder	28
Role of Chitinase 3–like 1 as a Biomarker in Multiple Sclerosis	28
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis	28
Effects of Vitamin D and Body Mass Index on Disease Risk and Relapse Hazard in Multiple Sclerosis	27
Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients With Multiple Sclerosis	27
Neuroprotective Properties of 4-Aminopyridine	27
Human Herpesvirus 6 Encephalitis in Immunocompetent and Immunocompromised Hosts	27
Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination	27
Targeting B cells to modify MS, NMOSD, and MOGAD	26
Interleukin-26, preferentially produced by T H 17 lymphocytes, regulates CNS barrier function	26
Secondary Progressive Multiple Sclerosis	26
Vaccine Hesitancy in Patients With Multiple Sclerosis	26
Clinical and Radiologic Disease Activity in Pregnancy and Postpartum in MS	26
MRI Characteristics of Autoimmune Encephalitis With Autoantibodies to GABAA Receptor	26
SARS-CoV-2 Infection in Multiple Sclerosis	26
Recovery From COVID-19 in Multiple Sclerosis	25
Neurological Autoimmunity Associated With Homer-3 Antibody	24
Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody	24
Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy	24
Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models	24
Autoimmune Encephalitis Resembling Dementia Syndromes	24
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis	24
Mesenchymal stem cell-derived neural progenitors in progressive MS	24
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients	24
Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis	24
B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease	24
Gut microbiota composition is associated with narcolepsy type 1	23
Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis	23
Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy	23
Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage	23
Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis	23
Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry	23
Immune Skew of Circulating Follicular Helper T Cells Associates With Myasthenia Gravis Severity	22
Direct economic burden of patients with autoimmune encephalitis in western China	22
CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis	22
Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome	22
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	22
Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis	22
Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With Campylobacter jejuni Infection	22
Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss	22
Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis	22
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab	22
Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis	22
Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease	22
Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis	22
Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder	21
Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors	21
Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19	21
Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom	21
Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders	21
Is MS affecting the CNS only?	21
Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar	20
Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis	20
CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity	20
CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS	20
Single-Cell Transcriptomics Identifies Brain Endothelium Inflammatory Networks in Experimental Autoimmune Encephalomyelitis	20
Intrathecal Antibody Production Against Epstein-Barr, Herpes Simplex, and Other Neurotropic Viruses in Autoimmune Encephalitis	20
Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis	20
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis	20
Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab	20
Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis	20
Mass Cytometry of CSF Identifies an MS-Associated B-cell Population	20
Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple Sclerosis	19
Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases	19
Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder	19
Absence of B Cells in Brainstem and White Matter Lesions Associates With Less Severe Disease and Absence of Oligoclonal Bands in MS	19
Autoantibodies Against the Purkinje Cell Protein RGS8 in Paraneoplastic Cerebellar Syndrome	19
Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder	19
Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection	19
Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis	19
Altered CSF Albumin Quotient Links Peripheral Inflammation and Brain Damage in MS	19
Paraneoplastic Cerebellar Degeneration	18
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis	18
Free light chains kappa can differentiate between myelitis and noninflammatory myelopathy	18
Hemophagocytic Lymphohistiocytosis Gene Mutations in Adult Patients Presenting With CLIPPERS-Like Syndrome	18
Exosomes From Subjects With Multiple Sclerosis Express EBV-Derived Proteins and Activate Monocyte-Derived Macrophages	18
Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year	18
Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy	18

Multiple Sclerosis	18
Anti-CD20 Depletes Meningeal B Cells but Does Not Halt the Formation of Meningeal Ectopic Lymphoid Tissue	18
Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome	18
Lymphocyte recovery after fingolimod discontinuation in patients with MS	18
Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis	18
CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection	18
Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity	18
Chitinase 3–like 1 and neurofilament light chain in CSF and CNS atrophy in MS	18
Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders	18
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America	18